Carvedilol can Replace Insulin in the Treatment of Type 2 Diabetes Mellitus

Ahmad, Anis

doi:10.4172/2155-6156.1000726

Cited by 6 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we used carvedilol, a third-generation beta-blocker agent with vasodilating action [35, 36] which can completely block the effects of excessive catecholamine, to investigate whether therapeutically targeting the adrenergic overdrive from chronic excess of basal norepinephrine in obesity could lead to metabolic benefits on the glucose metabolism. In agreement with the results from recent clinical studies [31, 33, 46], we found that carvedilol treatment during HFD-induced obesity improved glucose tolerance and insulin sensitivity possibly by suppressing the hepatic glucose overproduction and enhancing the muscular insulin signaling pathway.…”

Section: Discussionsupporting

confidence: 92%

Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice

Nguyen

Dang

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Catecholamine excess reflecting an adrenergic overdrive of the sympathetic nervous system (SNS) has been proposed to link to hyperleptinemia in obesity and may contribute to the development of metabolic disorders. However, relationship between the catecholamine level and plasma leptin in obesity has not yet been investigated. Moreover, whether pharmacological blockade of the adrenergic overdrive in obesity by the third-generation beta-blocker agents such as carvedilol could help to prevent metabolic disorders is controversial and remains to be determined. Using the high fat diet (HFD)-induced obese mouse model, we found that basal plasma norepinephrine, the principal catecholamine as an index of SNS activity, was persistently elevated and highly correlated with plasma leptin concentration during obesity development. Targeting the adrenergic overdrive from this chronic norepinephrine excess in HFD-induced obesity with carvedilol, a third-generation beta-blocker with vasodilating action, blunted the HFD-induced hepatic glucose over-production by suppressing the induction of gluconeogenic enzymes, and enhanced the muscular insulin signaling pathway. Furthermore, carvedilol treatment in HFD-induced obese mice decreased the enlargement of white adipose tissue and improved the glucose tolerance and insulin sensitivity without affecting body weight and blood glucose levels. Our results suggested that catecholamine excess in obesity might directly link to the hyperleptinemic condition and the therapeutic targeting of chronic adrenergic overdrive in obesity with carvedilol might be helpful to attenuate obesity-related metabolic disorders.

show abstract

Section: Discussionsupporting

confidence: 92%

Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice

Nguyen

Dang

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…31 Also, carvedilol reduces insulin resistance by sensitizing insulin receptors, inhibiting the sympathetic nervous system, which is significant in insulin resistance. 32 According to previous studies, it can be said that carvedilol can be a suitable drug in the treatment of cardiovascular diseases in diabetics.…”

Section: Discussionmentioning

confidence: 99%

Niosome-carvedilol protects DNA damage of supraphysiologic concentrations of insulin using comet assay: An in vitro study

2021

View full text Add to dashboard Cite

Introduction: Hyperinsulinemia occurs in type 2 diabetic patients with insulin resistance. This increase in insulin levels in the blood increases reactive oxygen species production and oxidative stress, resulting in DNA damage. Carvedilol (CRV) is a non-selective beta-blocker, and research has shown that this compound and its metabolites have anti-oxidative properties. Carvedilol can, directly and indirectly, reduce reactive oxygen species (ROS) and has a protective effect on DNA damage from oxidative stress. Given the insolubility of CRV in water, finding new methods to increase its solubility can be an essential step in research. This study aimed to determine whether carvedilol could have a protective effect on insulin-induced genomic damage. Methods: We treated cells with insulin alone, amorphous-CRV alone, and amorphous-CRV and niosomal-CRV with insulin and DNA damage were investigated using the comet method to achieve this goal. Results: Our results showed that insulin in the studied concentration has a significant genotoxic effect and non-cytotoxic at higher concentrations. CRV, both in amorphous and niosome form, reduced insulin-induced DNA damage by reducing ROS production. The comet assay results demonstrate that treating HUVEC cells in pretreatment condition with amorphous-CRV and niosome-CRV significantly reduces DNA damage of insulin.

show abstract

“…Carvedilol (1) was found to reduce insulin resistance by increasing the sensitivity of insulin receptors (IRs) and by reducing the activity of the sympathetic nervous system [50]. The adrenergic system, in part through beta-2 adrenergic receptors, regulates glucose and lipid metabolism in the liver, adipose tissue, and skeletal muscle.…”

Section: Carvedilolmentioning

confidence: 99%

Carbazoles: Role and Functions in Fighting Diabetes

Grande

Ioele²,

Caruso³

et al. 2022

Applied Sciences

View full text Add to dashboard Cite

Carbazole derivatives have gained a lot of attention in medicinal chemistry over the last few decades due to their wide range of biological and pharmacological properties, including antibacterial, antitumor, antioxidant, and anti-inflammatory activities. The therapeutic potential of natural, semi-synthetic or synthetic carbazole-containing molecules has expanded considerably owing to their role in the pathogenesis and development of diabetes. Several studies have demonstrated the ability of carbazole derivatives to reduce oxidative stress, block adrenergic hyperactivation, prevent damage to pancreatic cells and modulate carbohydrate metabolism. In this survey, we summarize the latest advances in the synthetic and natural carbazole-containing compounds involved in diabetes pathways.

show abstract

Carvedilol can Replace Insulin in the Treatment of Type 2 Diabetes Mellitus

Cited by 6 publications

References 21 publications

Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice

Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice

Niosome-carvedilol protects DNA damage of supraphysiologic concentrations of insulin using comet assay: An in vitro study

Carbazoles: Role and Functions in Fighting Diabetes

Contact Info

Product

Resources

About